Evan Sussman

CEO Granata Bio

Evan Sussman is the Co-Founder and Chief Executive Officer of Granata Bio, a women's health biotechnology company focused on developing and commercializing innovative therapies in fertility and reproductive health. Since cofounding Granata Bio in 2018, Evan has led the company's growth from inception, building a broad portfolio of commercial, late-stage, and novel reproductive health programs and securing more than $100 million in equity, royalty and strategic co-development financing to advance the company's portfolio. Under Evan's leadership, Granata Bio has established partnerships with leading global pharmaceutical and reproductive health companies, expanded its pipeline through the acquisition of Oviva Therapeutics, and advanced multiple fertility therapeutics through clinical and regulatory development. Prior to Granata Bio, Evan spent nearly a decade at EMD Serono, where he held leadership roles across the company's fertility pharmaceutical and fertility technology businesses. Earlier in his career, he held commercial roles at United Therapeutics, CV Therapeutics, and Eli Lilly. Evan received his MBA from the Yale School of Management and his BA from Brown University.